Transferrin-mediated Pulmonary GATA3 siRNA Delivery in a Murine Model of Allergic Asthma
Summary
Asthma continues to pose a major clinical burden despite the availability of modern biologic therapies. In eosinophilic asthma, the transcription factor GATA3 is a key regulator of Th 2 differentiation and type 2 cytokine production and therefore represents an attractive target for siRNA-based intervention. We previously established a transferrin-functionalized polyethyleneimine (Tf-PEI) polyplex system for targeted siRNA delivery to human T-cells. Here, we aimed to translate and adapt this platform to the murine system to enable therapeutic evaluation in a preclinical asthma model.
Asthma continues to pose a major clinical burden despite the availability of modern biologic therapies. In eosinophilic asthma, the transcription factor GATA3 is a key regulator of Th 2 differentiation and type 2 cytokine production and therefore represents an attractive target for siRNA-based intervention. We previously established a transferrin-functionalized polyethyleneimine (Tf-PEI) polyplex system for targeted siRNA delivery to human T-cells. Here, we aimed to translate and adapt this platform to the murine system to enable therapeutic evaluation in a preclinical asthma model. Accordingly, a murine Tf-PEI polyplex system was developed for targeted delivery of siRNA to activated T-cells in the lung. Murine CD4⁺ T-cells were polarized toward a Th 2 phenotype and used to assess nanoparticle uptake and functional GATA3 silencing in vitro . The performance of the polyplexes was further evaluated in activated murine precision-cut lung slices and in an ovalbumin-induced murine asthma model. While non-targeted PEI showed high cellular uptake, this did not translate into efficient or sequence-specific gene silencing. In contrast, Tf-functionalized polyplexes enabled functional GATA3 knockdown, with partially functionalized Tf-PEI outperforming fully functionalized formulations. The optimized 50% Tf-PEI blend achieved the strongest silencing in primary Th 2 cells and lung slices and mediated an approximate 50% reduction in GATA3 mRNA levels in vivo . In the murine asthma model, this was accompanied by reduced inflammatory cell infiltration, improved lung histopathology, and the lack of pronounced inflammatory responses under the tested conditions. Collectively, our results demonstrate that precise tuning of transferrin ligand density critically controls functional siRNA delivery to pulmonary T-cells in vivo , establishing a rational design framework for targeted RNA nanotherapeutics against type 2 airway inflammation.
Abstract from Europe PMC — Research Square. This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
Targeted delivery platforms for in vivo immune cell engineering: emerging strategies for cancer immunotherapy
Molecular therapy. Nucleic acidsHuman T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles
Journal of controlled release : official journal of the Controlled Release SocietyThe role of glycocalyx-protein corona interactions in the cell type-specific uptake of mRNA nanocarriers
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.
